

25th March 2025

The ISH Venues, 1 Park Crescent, Regents Park, London.

Programme

Future-proofing CHB management in the UK: From Diagnosis to Functional Cure

09:15 – 09:45	Arrival - Registration and coffee
09:45 - 11.15	Session 1 – Public Health (Dr Monica Desai & Prof. Dan Forton)
09:50 – 10:05	Hepatitis B- an overview of progress towards the Global Health Sector Strategy on viral hepatitis in England - Dr Ruth Simmons, UKHSA
10:05 – 10:20	Current challenges, evidence and gaps in the evidence base for hepatitis B prevention, diagnosis, and linkage to care - Dr David Leeman, UKHSA
10:20 – 10:35	UK update of Hepatitis B - Dr Stuart Flanagan, UCLH
10.35 - 10.50	HBV: diagnosis, monitoring and pathways – NHS England' - Mark Gillyon-Powell, NHSE
10:50 – 11:15	Panel Discussion & questions
11.15 – 11.30	Coffee and Exhibition
11.30 - 13:00	Session 2 – Elimination & Global impact of HBV (Dr Sema Mandal & Prof. Maud Lemoine)
11:35 – 11:55	Outcomes from ED testing - Dr Doug MacDonald, The Royal Free Hospital
11:55 – 12:15	How does HBV in the UK differ from the global disease burden - Dr Shevanthi Nayagam, Imperial College London
12:15 – 12:35	When does HBV treatment not work? - Prof Philippa Matthews, The Francis Crick & UCLH

12:35 – 12:50 Panel Discussion & questions

12:50 – 14:00	Lunch and Exhibition
14:00 - 15:20	Session 3 – Child Health & Patient Engagement (Dr Ahmed Elsharkawy, Dr Tori Appleby & Joy Ko)
14:05 – 14:25	HBV in pregnancy & Paediatrics - Prof Eleni Nastouli, UCLH
14:25 – 14.45	Digital health care (HepB&Me) - Dr Almuthana Mohamed, QMUL
14:45 – 15:05	Putting the patient in the driving seat - Dr Kosh Agarwal, King's College Hospital
15:05 – 15:20	Panel Discussion & questions
15.20 – 15.35	Coffee and Exhibition
15:35 – 17:00	Session 4 – Hepatitis Delta, Prescribing & Training (Helen Boothman & Prof. Patrick Kennedy)
15:35 – 17:00 15:35 – 15:55	
	(Helen Boothman & Prof. Patrick Kennedy) HDV: The role of Bulevirtide & novel therapies
15:35 – 15:55	 (Helen Boothman & Prof. Patrick Kennedy) HDV: The role of Bulevirtide & novel therapies Dr Uppy Gill, QMUL The role of the Pharmacist in supporting CHB & HDV management
15:35 – 15:55 15:55 – 16.15	 (Helen Boothman & Prof. Patrick Kennedy) HDV: The role of Bulevirtide & novel therapies Dr Uppy Gill, QMUL The role of the Pharmacist in supporting CHB & HDV management Sital Shah, King's College Hospital Treating patients with viral hepatitis - challenges from UK trainees' perspective

BASL would like to thank the following pharmaceutical companies who provided funding for this meeting.







Our sponsors and supporters for the event have had no influence over, or input into the content of the materials used at this meeting including the programme and selection of speakers.

For queries, please contact kim@basl.org.uk Tel. 01543 442154